Sinopharm successfully listed on the main board of Hong Kong Stock Exchange
Sinopharm Group Co. Ltd., which Fosun Pharmaceutical Group has equity participation, was officially listed on the main board of Hong Kong Stock Exchange on Sep. 23rd. The total market value of Sinopharm Group Limited is more than 36.2 billion HK$ by calculating in 16 HK$ per share of the issue price, which is the largest market value of listed pharmaceutical companies in China.
This issuing of Sinopharm Group has attracted many investors to compete against each other to subscribe, has oversubscribed by 570 times during Hong Kong public issuing, and has been frozen capital of 497.75 billion HK$. Before exercising of the over-allotment option, the net funds of this global issuing raised approximately 8.41 billion HK$; in case exercise the over-allotment option, the net funds raised will reach about 9.67 billion HK$.
Since Fosun Pharmaceutical Group invested Sinopharm Group in 2003, the revenue of Sinopharm Group over the past six years achieved a compound growth of 36% annually, and 56% of net profit in a high-speed development, which strengthened its leading position in pharmaceutical distribution business in China. The revenue of Sinopharm Group achieved 38.19 billion RMB in 2008, and this figure exceeded the sum of the second’s and the third’s of the industry, and absolutely No. 1. The net profit under Hong Kong criterion even achieved 590 million RMB with YoY increased 54%. The first 5 months in 2009, the sales revenue of Sinopharm Group achieved 18.05 billion RMB with YoY increased 20% and achieved net profit 420 million RMB with YoY increased 42%.
The successful listing of Sinopharm Group shows the accurate judgment of Fosun Pharmaceutical Group to the pharmaceutical distribution industry, as well as the great investment vision to Sinopharm Group. Analysts believe that the development of pharmaceutical distribution industry is at the concentration stage, the characteristics of its natural monopolies of this industry will decline the number of players, but the growth speed of some leading enterprises will continue higher than the average level. Benefiting from aging, rising of resident income level, the new medical reform and other factors, the environment of Chinese pharmaceutical industry will become better in the next 10 years. As the largest pharmaceutical distribution enterprise in China, Sinopharm Group will fully take the advantage of these favorable factors. The successful listing on the main board of Hong Kong provided a broad capital platform for Sinopharm Group, and the abundant fund collected through this issuing will definitely accelerate its future development.
This issuing of Sinopharm Group has attracted many investors to compete against each other to subscribe, has oversubscribed by 570 times during Hong Kong public issuing, and has been frozen capital of 497.75 billion HK$. Before exercising of the over-allotment option, the net funds of this global issuing raised approximately 8.41 billion HK$; in case exercise the over-allotment option, the net funds raised will reach about 9.67 billion HK$.
Since Fosun Pharmaceutical Group invested Sinopharm Group in 2003, the revenue of Sinopharm Group over the past six years achieved a compound growth of 36% annually, and 56% of net profit in a high-speed development, which strengthened its leading position in pharmaceutical distribution business in China. The revenue of Sinopharm Group achieved 38.19 billion RMB in 2008, and this figure exceeded the sum of the second’s and the third’s of the industry, and absolutely No. 1. The net profit under Hong Kong criterion even achieved 590 million RMB with YoY increased 54%. The first 5 months in 2009, the sales revenue of Sinopharm Group achieved 18.05 billion RMB with YoY increased 20% and achieved net profit 420 million RMB with YoY increased 42%.
The successful listing of Sinopharm Group shows the accurate judgment of Fosun Pharmaceutical Group to the pharmaceutical distribution industry, as well as the great investment vision to Sinopharm Group. Analysts believe that the development of pharmaceutical distribution industry is at the concentration stage, the characteristics of its natural monopolies of this industry will decline the number of players, but the growth speed of some leading enterprises will continue higher than the average level. Benefiting from aging, rising of resident income level, the new medical reform and other factors, the environment of Chinese pharmaceutical industry will become better in the next 10 years. As the largest pharmaceutical distribution enterprise in China, Sinopharm Group will fully take the advantage of these favorable factors. The successful listing on the main board of Hong Kong provided a broad capital platform for Sinopharm Group, and the abundant fund collected through this issuing will definitely accelerate its future development.